$459.41
0.05%
Nasdaq, Jul 07, 10:00 pm CET
ISIN
US92532F1003
Symbol
VRTX
Sector
Industry

Vertex Pharmaceuticals Stock price

$459.41
+13.26 2.97% 1M
+51.09 12.51% 6M
+56.71 14.08% YTD
-22.48 4.67% 1Y
+165.24 56.17% 3Y
+160.35 53.62% 5Y
+331.93 260.38% 10Y
+442.58 2,629.71% 20Y
Nasdaq, Closing price Mon, Jul 07 2025
-0.21 0.05%
ISIN
US92532F1003
Symbol
VRTX
Sector
Industry

Key metrics

Basic
Market capitalization
$118.0b
Enterprise Value
$111.9b
Net debt
positive
Cash
$6.2b
Shares outstanding
257.0m
Valuation (TTM | estimate)
P/E
negative | 25.1
P/S
10.6 | 9.7
EV/Sales
10.1 | 9.2
EV/FCF
negative
P/B
7.2
Financial Health
Equity Ratio
72.8%
Return on Equity
-3.3%
ROCE
22.0%
ROIC
87.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$11.1b | $12.2b
EBITDA
$4.4b | $5.6b
EBIT
$4.2b | $5.4b
Net Income
$-988.9m | $4.7b
Free Cash Flow
$-1.3b
Growth (TTM | estimate)
Revenue
9.0% | 10.5%
EBITDA
-1.6% | 21.4%
EBIT
-1.8% | -
Net Income
-124.6% | 979.2%
Free Cash Flow
-136.2%
Margin (TTM | estimate)
Gross
86.0%
EBITDA
39.7% | 45.9%
EBIT
37.9%
Net
-8.9% | 38.7%
Free Cash Flow
-11.3%
More
EPS
$-3.8
FCF per Share
$-4.9
Short interest
1.8%
Employees
6k
Rev per Employee
$1.8m
Show more

Create a Free Account to create an Vertex Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Vertex Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

40 Analysts have issued a Vertex Pharmaceuticals forecast:

24x Buy
60%
15x Hold
38%
1x Sell
3%

Analyst Opinions

40 Analysts have issued a Vertex Pharmaceuticals forecast:

Buy
60%
Hold
38%
Sell
3%

Financial data from Vertex Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
11,100 11,100
9% 9%
100%
- Direct Costs 1,551 1,551
16% 16%
14%
9,549 9,549
8% 8%
86%
- Selling and Administrative Expenses 1,518 1,518
23% 23%
14%
- Research and Development Expense 3,821 3,821
13% 13%
34%
4,410 4,410
2% 2%
40%
- Depreciation and Amortization 202 202
3% 3%
2%
EBIT (Operating Income) EBIT 4,208 4,208
2% 2%
38%
Net Profit -989 -989
125% 125%
-9%

In millions USD.

Don't miss a Thing! We will send you all news about Vertex Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vertex Pharmaceuticals Stock News

Positive
The Motley Fool
about 20 hours ago
Don't let the summer heat keep you from making money. July is a great time to invest in the stocks of top-tier companies.
Neutral
The Motley Fool
3 days ago
Forget the market sell-off experienced earlier this year. Stocks are hot again.
Positive
Reuters
7 days ago
Vertex said on Tuesday that its next-generation drug, Alyftrek, gained European Commission approval for the treatment of cystic fibrosis.
More Vertex Pharmaceuticals News

Company Profile

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Head office United States
CEO Reshma Kewalramani
Employees 6,100
Founded 1989
Website www.vrtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today